The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal swab specimens from individuals suspected of COVID-19 or asymptomatic individuals. Used with the LumiraDx Platform the test delivers rapid results at the point of care.
SARS-CoV-2 Ag Test
.jpg.ashx?maxwidth=140&maxheight=60&bgcolor=white&mode=pad)
Test benefits
The use of a LumiraDx SARS-CoV-2 Ag Test on the LumiraDx Instruments will enable the physician to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection.
- Easy to implement in point of care settings
- Clinical performance
- 7.6% positive percent agreement
- 96.6% negative percent agreement
- Analytical performance with a limit of detection of 32 TCID50/mL
- RT-PCR comparable results within 12 days of onset of symptoms
Product Overview
.jpg.ashx?width=100&height=100&bgcolor=white)
